TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Artiva Biotherapeutics, Inc. ( (ARTV) ) is now available.
On November 12, 2025, Artiva Biotherapeutics announced positive initial safety and translational data from clinical trials of AlloNK in combination with rituximab or obinutuzumab for treating autoimmune diseases. The trials demonstrated that AlloNK was well tolerated, with no serious adverse events, and showed consistent B-cell depletion, comparable to CD19-auto-CAR-T therapies. This data supports the feasibility of administering AlloNK in outpatient and community settings, potentially addressing unmet needs in refractory rheumatoid arthritis, with plans for further clinical response data and FDA interactions in 2026.
The most recent analyst rating on (ARTV) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Artiva Biotherapeutics, Inc. stock, see the ARTV Stock Forecast page.
Spark’s Take on ARTV Stock
According to Spark, TipRanks’ AI Analyst, ARTV is a Neutral.
Artiva Biotherapeutics, Inc. faces significant challenges with profitability and cash flow, reflected in a low financial performance score. While technical indicators show some positive momentum, the negative valuation metrics weigh heavily on the overall score.
To see Spark’s full report on ARTV stock, click here.
More about Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing effective, safe, and accessible cell therapies for autoimmune diseases and cancers. Their lead program, AlloNK, is an allogeneic, off-the-shelf, non-genetically modified NK cell therapy designed to enhance the antibody-dependent cellular cytotoxicity effect of monoclonal antibodies to drive B-cell depletion. Artiva’s pipeline also includes CAR-NK candidates targeting both solid and hematologic cancers.
Average Trading Volume: 2,121,547
Technical Sentiment Signal: Buy
Current Market Cap: $89.4M
Learn more about ARTV stock on TipRanks’ Stock Analysis page.